Australia · Delayed Price · Currency is AUD Aroa Biosurgery Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 23% to NZD 104 million, driven by Myriad’s strong performance and expanding direct sales. Board changes and strategic investments in sales infrastructure support future growth, while Ovitex and Symphony face market challenges but offer significant long-term potential.
-
Revenue grew 23% to NZD 104 million, driven by Myriad's 54% growth and high margins. Profitability and strong cash flow were achieved, with significant investments planned for sales expansion and Symphony's market opportunity. FY 2027 guidance targets 13%–23% revenue growth.
-
Clinical and commercial momentum is strong, with Myriad outperforming in trauma and Symphony poised to benefit from US reimbursement changes. FY26 revenue and EBITDA are tracking toward the upper end of guidance, with ongoing profitability and positive cash flow.
-
Revenue grew 13% YoY to $44.9M with positive EBITDA and strong cash flow. Myriad sales surged 33%, and Tela Bio expanded its commercial team and product pipeline. CMS reimbursement changes may disrupt competitors, creating new opportunities.
-
Achieved a fourth consecutive quarter of positive cash flow, with record Myriad sales up over 30% year-over-year and strong cash reserves. Guidance for revenue and EBITDA was reiterated, while U.S. reimbursement changes and tariffs present manageable risks.
-
Sales and cash flow tracked in line with expectations, with strong Myriad and TELA Bio performance. Guidance for revenue and EBITDA was reaffirmed, and CMS reimbursement proposals could benefit Symphony if enacted.
Fiscal Year 2025
-
The meeting reviewed strong 23% growth, margin improvements, and positive cash flow, with continued investment in product development and international expansion. No dividend is planned as focus remains on reinvestment. Key risks include U.S. tariffs and TELA Bio's performance.
-
Revenue grew 23% to AUD 84.7 million, with first positive normalized EBITDA of AUD 4.2 million and strong cash position. Myriad drove growth, while guidance for FY 2026 targets 10–20% revenue increase and continued profitability.
-
Revenue and EBITDA guidance were reaffirmed, with strong Myriad and TELA Bio sales growth. Cash flow remained positive for the second consecutive quarter, and the cash balance reached $22 million. Over 100 peer-reviewed studies now support the ECM platform.
-
Positive operating cash flow and strong Myriad sales drove improved profitability, despite softer TELA Bio partnership sales. Updated guidance reflects revenue growth, ongoing US expansion, and robust clinical outcomes, with Myriad showing low infection rates and significant cost savings.
-
Strong first-half revenue growth, high gross margins, and robust sales momentum for Myriad and TELA Bio support reaffirmed full-year guidance. Clinical evidence and new product launches underpin continued expansion in a large addressable market.
-
Net cash flow from operations improved significantly, with expectations for positive operating cash flow in the second half. Myriad and OviTex drive growth, supported by strong clinical data and regulatory approvals, while guidance for FY 2025 remains unchanged.
-
Quarterly cash receipts reached AUD 17.8 million with a strong cash position and robust growth in Myriad and OviTex product lines. Revenue and EBITDA guidance were maintained, with significant clinical and commercial momentum and expanding global reach.
Fiscal Year 2024
-
The meeting reviewed strong Myriad sales growth, ongoing clinical studies, and strategic expansion, while addressing challenges in market uptake and profitability. Board elections and resolutions proceeded smoothly, with shareholder engagement on humanitarian and market access topics.